Compare AVO & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVO | INBX |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2020 | 2024 |
| Metric | AVO | INBX |
|---|---|---|
| Price | $12.80 | $82.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $17.00 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 991.5K | 256.4K |
| Earning Date | 06-04-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.92 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,391,200,000.00 | $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.68 | ★ 550.00 |
| 52 Week Low | $10.07 | $20.55 |
| 52 Week High | $15.53 | $155.29 |
| Indicator | AVO | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 52.55 | 41.21 |
| Support Level | $11.44 | $69.57 |
| Resistance Level | $12.89 | $85.97 |
| Average True Range (ATR) | 0.41 | 4.66 |
| MACD | -0.07 | -0.25 |
| Stochastic Oscillator | 39.52 | 32.87 |
Mission Produce Inc produces, packs, and distributes mainly Hass avocados to retail, wholesale, and food service customers, offering pre-ripe and ripened fruit tailored to customer specifications through its network of ripening facilities. The Company operates through three segments: Marketing & Distribution, which sources and distributes fruit globally and generates the majority of revenue; International Farming, which owns and operates avocado orchards and supplies fruit mainly to Marketing & Distribution, with operations principally in Peru and Guatemala; and Blueberries, which farms blueberries sold under an exclusive marketing agreement. The Company's operations span Peru, the United States, Guatemala, Mexico, Europe, and Canada.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.